01.04.19

Oculis In-Licenses Phase 2 Topical Anti-TNF Alpha Antibody From Novartis

Source: Oculis

Oculis has entered into an agreement to in-license a novel topical anti-TNF alpha antibody from Novartis.

Terms of the deal were not disclosed.

The compound, named LME 636, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials including controlled studies under IND by Novartis Institute of Biomedical Research. The studies demonstrated a promising profile for treating inflammatory conditions of the anterior segment of the eye, including dry eye disease.

The in-licensing of LME636, which will be renamed OCS-02, expands Oculis’ portfolio of novel topical therapies for major ophthalmic diseases, and offers Oculis the opportunity to address unmet medical needs of patients with potentially the first topical anti-TNF alpha therapy for ophthalmic indications.

Oculis plans to develop OCS-02 in parallel to its other ongoing pipeline programs. It will be supported by new funds raised in the extension of its Series B financing round, announced separately today.

“This agreement is part of our ongoing strategy to access multiple sources of technologies and compounds that bolster our portfolio of innovative products to treat eye diseases. We are looking forward to working with the ophthalmology community on the rapid development of this promising therapy,” Dr. Riad Sherif, Chief Executive Officer of Oculis, said in a company news release.

Related Content